Latest news with #woundcare
Associated Press
a day ago
- Health
- Associated Press
Why Sleep Matters: Optimum Wound Care Shares Key Link Between Rest and Wound Recovery
Research-backed guidance sheds light on the healing benefits of quality sleep in wound care. 'We regularly observe how non-clinical factors such as rest, nutrition, and stress management affect patient recovery.'— Mosayeb (Moe) Karimi, FNP LOUISVILLE, KY, UNITED STATES, August 11, 2025 / / -- Optimum Wound Care, a provider of advanced wound care in Louisville, has released new guidance on the important relationship between sleep and the body's healing process. The educational resource emphasizes that quality rest is a foundational component in wound recovery, especially for patients managing chronic wounds or undergoing long-term treatment. Recent clinical studies have shown that adequate sleep supports tissue regeneration, immune function, and hormonal balance all of which are essential for effective wound healing. The Optimum Wound Care's recent article outlines these connections, aiming to raise awareness among patients and caregivers about the role of sleep in overall recovery outcomes. 'We regularly observe how non-clinical factors such as rest, nutrition, and stress management affect patient recovery,' said Dr. Mosayeb (Moe) Karimi, Medical Director at Optimum Wound Care. 'Sleep, in particular, has a measurable influence on wound healing. Patients who prioritize consistent, restorative sleep often experience more favorable healing progress.' According to Optimum Wound Care, sleep deprivation can disrupt the body's ability to produce cytokines proteins that regulate inflammation and healing. This can lead to slower recovery, increased risk of infection, and prolonged treatment timelines. Individuals with existing conditions such as diabetes or circulatory issues may be especially vulnerable to the effects of poor sleep. The center's article also discusses how certain sleep disorders, including insomnia and sleep apnea, can impair oxygen delivery and reduce the effectiveness of natural healing mechanisms. These insights are part of Optimum Wound Care's broader approach to wound care, which integrates lifestyle education with evidence-based medical treatment. 'Patient education is an important part of what we do,' Dr. Karimi added. 'When we inform patients about how their daily habits like sleep patterns can affect their recovery, we empower them to take a more active role in their healing process.' In addition to traditional wound treatments, Optimum Wound Care encourages patients to develop healthy sleep routines. Recommendations include setting consistent bedtimes, limiting screen use before sleep, and addressing underlying medical issues that may disrupt rest. These strategies, while not a substitute for medical intervention, can significantly enhance the effectiveness of wound care. The article, How Sleep Affects Wound Healing and Recovery, is available on the Optimum Wound Care's website and is intended for both patients and clinicians. It reflects the center's continued commitment to improving recovery through holistic, patient-centered care. About Optimum Wound Care Optimum Wound Care is a Louisville-based medical clinic specializing in advanced wound care and recovery solutions. With a multidisciplinary team of physicians, nurses, and specialists, the center provides customized treatment for chronic wounds, diabetic ulcers, pressure injuries, and other complex conditions. Optimum Wound Care is committed to improving patient outcomes through evidence-based care, education, and compassionate support. Healing starts here. Trust Optimum Wound Care to deliver expert, patient-centered solutions that accelerate recovery and improve outcomes. Connect with our care team today and take the first step toward optimum healing. Mosayeb (Moe) Karimi Optimum Wound Care (OWC) +1 502-293-5665 [email protected] Visit us on social media: Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Globe and Mail
4 days ago
- Health
- Globe and Mail
CEO James Brady Washburn Advocates for Compassionate Innovation in Wound Care
Former Division I athlete and healthcare leader calls for more attention to vulnerable patient populations and frontline caregivers As the demand for high-quality, patient-centered wound care grows across the U.S., James Brady Washburn, CEO of Mid South Wound LLC, is calling on healthcare providers and leaders to reframe how they approach care for chronic wounds and post-acute recovery patients. His message: 'Wound care is not just clinical—it's personal. It's where compassion meets consistency.' Washburn, a seasoned healthcare executive and former Division I football player, now leads one of the region's most respected wound care companies, known for its commitment to bedside excellence and provider-driven innovation. Under his leadership, Mid South Wound LLC has grown into a trusted resource for long-term care facilities, hospitals, and rehabilitation centers. 'We're treating more than wounds—we're treating people who are often overlooked in a fast-moving healthcare system,' Washburn said. 'They need advocates. They need dignity. That starts with showing up every day with purpose.' A Call to Prioritise Underserved Patients According to the National Institutes of Health, an estimated 6.7 million Americans live with chronic wounds, and that number is expected to rise due to aging populations and increasing rates of diabetes and obesity. Yet wound care remains an underfunded and underrecognised area in the broader healthcare landscape. Washburn believes this gap must be addressed with urgency. 'We have some of the most vulnerable people—seniors, veterans, patients recovering from surgery—suffering in silence,' he explained. 'If wound care is done right, it restores not just skin, but confidence, mobility, and quality of life.' Leadership Rooted in Discipline and Legacy Washburn's personal background adds weight to his message. The son of longtime NFL coach Jim Washburn and brother of Jeremiah Washburn, current coach for the Philadelphia Eagles, Brady grew up immersed in the values of discipline, teamwork, and relentless preparation. He played college football at Clemson University and Appalachian State University, before earning a Bachelor of Business Administration from Lipscomb University in 2007. These experiences shaped his leadership style—driven yet humble, strategic yet grounded in relationships. 'Football taught me to lead under pressure,' Washburn said. 'But it also taught me to respect every role on the team. That's how I lead our clinicians—like teammates, not staff.' Bridging Innovation and Humanity At Mid South Wound LLC, Washburn oversees strategic growth, provider recruitment, and clinical quality. But he stays connected to the day-to-day work of care teams and patients. He advocates for healthcare companies to balance business efficiency with empathy—especially in fields like wound care, where treatment is often intimate and ongoing. 'You can't automate human touch,' he said. 'That's why I push for training, collaboration, and systems that support—not replace—the caregiver.' Washburn is currently preparing to launch Mid South Wound's new website, which will serve as a resource for facilities, partners, and families seeking expert wound care services in the Southeast. What the Public Can Do Washburn encourages individuals and families to: Ask more questions about wound care options for loved ones in nursing homes or hospitals Support local clinicians and nurses who provide ongoing wound care treatment Advocate for better funding and awareness in post-acute and chronic wound care Explore careers in wound care, which offers high demand and meaningful patient impact 'If you know someone recovering from surgery, in long-term care, or with a chronic condition—ask how their wound care is being handled,' Washburn urged. 'Your attention might change their outcome.' Final Word: Lead With Integrity, Serve With Heart Whether it's mentoring his son, Cash Washburn, a rising football recruit, or managing a growing clinical operation, Washburn keeps one principle at the center of it all—service through leadership. 'Leadership isn't about being loud,' he said. 'It's about lifting others up and building something that lasts. In football, in business, and in healthcare—it all comes back to that.' CALL TO ACTION Don't overlook wound care—it's where healing begins. Learn how you can support patients, caregivers, and wound care professionals in your own community. Awareness, action, and compassion go a long way. Media Contact: Read the full Interview, here. Email: jameswashburn@ Media Contact Contact Person: James Brady Washburn Email: Send Email Country: United States Website:
Yahoo
5 days ago
- Business
- Yahoo
Solventum raises annual profit forecast on strength in surgical equipment
(Reuters) -Medical device maker Solventum raised full-year adjusted profit forecast on Thursday, driven by strong sales of its wound care and surgical sterilization products alongside lower expenses. Medical device makers have benefited from a surge in demand as more people, particularly older Americans, seek health care services and surgical procedures. Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities. More than half of its revenue comes from its MedSurg business, which provides wound dressings and surgical equipment. Sales in the segment rose 4.8% to $1.22 billion during the quarter. Earlier in the day, Solventum's peer Zimmer Biomet Holdings also raised its annual profit forecast as it anticipates lower-than-expected tariff impact. Last quarter, Solventum estimated tariff headwinds of $80 million to $100 million for 2025, translating to an earnings per share impact of 35 cents to 45 cents. However, analysts now note that Solventum's tariff risk has eased following the recent de-escalation of U.S.-China trade tensions. The company now expects its 2025 adjusted profit per share to be in the range of $5.80 to $5.95, compared with previously projected adjusted profit of $5.45 to $5.65. On an adjusted basis, the company earned second-quarter profit per share of $1.69, compared with analysts' average estimates of $1.44, according to data compiled by LSEG.
Yahoo
30-07-2025
- Business
- Yahoo
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX's Leading Placental Allograft Portfolio and Vaporox's Vaporous Hyperoxia Treatment Device MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ('MIMEDX' or the 'Company') and Vaporox, Inc. ('Vaporox') today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions. Vaporox is a privately held, Denver-based company that has developed and is commercializing its patented Vaporous Hyperoxia Therapy ('VHT') device for treating chronic and hard-to-heal wounds. VHT delivers two healing modalities, ultrasonic mist and concentrated oxygen, in a single device and has received a 510(k) clearance from the U.S. Food & Drug Administration ('FDA') to treat nine types of wounds, including Diabetic Foot Ulcers ('DFUs'), Venous Leg Ulcers ('VLUs') and Pressure Ulcers (bed sores). 'We are thrilled to continue delivering on our strategic goal of greater portfolio diversification through this collaboration with Vaporox,' commented Joseph H. Capper, MIMEDX Chief Executive Officer. 'Together with our leading placental allografts, VHT will offer clinicians across numerous care settings another proven option to treat chronic, hard-to-heal wounds. We view this as a highly complementary addition that will help us grow in this important setting, where patients with difficult wounds often begin their recovery.' 'Vaporox is excited to partner with a market leader in wound care to expand awareness and adoption of our technology,' said Alan Sage, Chief Executive Officer of Vaporox. 'We believe co-promotion with MIMEDX will accelerate our market penetration and create a synergistic offering—allowing us to reach more patients with these highly complementary offerings.' VHT has been the subject of three IRB clinical studies, each of which demonstrated wound healing rates exceeding 80% at 20 weeks when combined with standard wound care. Additionally, Vaporox's VHT is an adjunct therapy that has shown promising signs of efficacy in real-world use cases with MIMEDX's Advanced Wound Care products, such as EPIFIX®. About Vaporox, technology represents a breakthrough in treating chronic wounds. The company is focused on superior healing outcomes while reducing costs across a wide range of healthcare settings. With strong clinical results and growing adoption, Vaporox empowers providers to restore hope and healing for patients suffering from chronic wounds. For additional information, please visit About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit Contact:Matt NotarianniInvestor Relations470-304-7291mnotarianni@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-07-2025
- Business
- Yahoo
BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived products for advanced wound care, announces it will release its second quarter 2025 financial results on Thursday, August 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature a review of second quarter results and an update on the Company's Form 10 filing and Nasdaq uplisting, led by CEO Jason Matuszewski and CFO Michael Fortunato. To register for the event, please click HERE. Conference Call & Webcast Information: Conference ID: 9695874 North America Toll-Free: (800) 715-9871 International Toll: +1 (646) 307-1963 Webcast Link: Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign up for the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for advanced wound care. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem's quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks ('AATB') and adhere to Good Tissue Practices (cGTP) and Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion™ and American Amnion™ AC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate', 'plan,' 'outlook,' 'project,' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Contact BioStem Technologies, Inc.: BioStem Technologies, HoldsworthDirector of Investor Relations E-Mail: adam@ Phone: 917-497-9287 Or Gilmartin GroupPhilip Trip Taylor, PrincipalE-Mail: philip@ 415-937-5406Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
